MedTrace Logo

Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

NCT01113476 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2022-09-02

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of Abraxane (nab-paclitaxel), Gemzar (gemcitabine), and Avastin (bevacizumab) that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Conditions

Interventions

DRUG

Nab-paclitaxel

Starting dose of 50 mg/m\^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)

DRUG

Bevacizumab

Starting dose of 5 mg/m\^2 on Day 1 + 15 every 28 days (+/- 2 days)

DRUG

Gemcitabine

1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • David S. Hong, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-27
Primary Completion
2022-08-12
Completion
2022-08-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01113476 on ClinicalTrials.gov